| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/27/2005 | US20050020491 A decorin core protein or a fragment covalently linked to a galactosaminoglycan polysaccharide, and the decorin core protein acts as an anticoagulant and as a carrier for the delivery of an antithrombotic galactosaminoglycan to fibrinogen. |
| 01/27/2005 | US20050020490 Eficiency purification of glucan, mannan, mannan-protein complex from yeasts; reducing antibiotics in animal feeds |
| 01/27/2005 | US20050020489 Use of hcg and lh in controlled ovarian hyperstimulation |
| 01/27/2005 | US20050020488 Process for preparing glycopeptide phosphonate derivatives |
| 01/27/2005 | US20050020485 Methods and compositions for oxygen transport comprising modified hemoglobin in plasma |
| 01/27/2005 | US20050020484 Using protein mixture of lactoferrin and albumin; anticholesterol agents; antilipemic agents; obesity, hypotensive agents, antidiabetic agents |
| 01/27/2005 | US20050020483 Sigma ligands for neuronal regeneration and functional recovery |
| 01/27/2005 | US20050019931 Nucleic acids encoding antifungal drug targets and methods of use |
| 01/27/2005 | US20050019929 Deleted adenovirus vectors and methods of making and administering the same |
| 01/27/2005 | US20050019927 DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER |
| 01/27/2005 | US20050019923 Nucleotide sequences comprising cationic polypropylenimine dendrimer and diaminobutane core for use as tool in delivery of drug agents and tissue targeted therapy |
| 01/27/2005 | US20050019921 Method for combined sequential agent delivery and electroporation for cell structures and use thereof |
| 01/27/2005 | US20050019918 Nucleotide sequences for controlling mitogen activated kinase expression for use in the treatment of cell proliferative disorders; antisense oligonucleotides |
| 01/27/2005 | US20050019915 Oligonucleotides for use in controlling expression of gene coding polypeptide associated with catalyzing the dismutation of superoxide to hydrogen peroxide; antiproliferative agents; antitumor agents; gene expression inhibition |
| 01/27/2005 | US20050019890 Nitrilase homologs |
| 01/27/2005 | US20050019889 Human osteoclast derived cathepsin |
| 01/27/2005 | US20050019872 PC-LECTIN protein; vaccines and diagnostic marker for prostate cancer |
| 01/27/2005 | US20050019870 Monoclonal antibody specific to tuumor associated prostate gene for use diagnostic tool in detection and classification of cell proliferative disorders |
| 01/27/2005 | US20050019868 Transgenic mouse comprising nucleotide sequences coding transport protein for use as tool in identifying modulators for prevention and treatment of cell proliferative disorders |
| 01/27/2005 | US20050019866 Nucleotide sequences coding membrane protein for use in diagnosis, detection, prevention and/or treatment of cell proliferative disorders |
| 01/27/2005 | US20050019860 Novel C-type lectin and gene thereof |
| 01/27/2005 | US20050019858 Novel human cytokine/steroid receptor protein |
| 01/27/2005 | US20050019847 Using preferential antibodies to identify ubiquitin-like protein (ISG15); immunodiagnostics; wound healing agents |
| 01/27/2005 | US20050019846 Using ornithine carbamoyltransferase (OCT) as diagnostic tool in screening for antifungal agents; fungicides and disease resistant plants |
| 01/27/2005 | US20050019840 Non-endogenous, constitutively activated known G protein-coupled receptors |
| 01/27/2005 | US20050019838 Nucleotide sequences coding modular protein domains (PDZ) for use in identifying modulators for treatment of cell proliferative/differentiation, metabolic, immunological or nervous system disorders |
| 01/27/2005 | US20050019830 Methods of screening for TRPM5 modulators |
| 01/27/2005 | US20050019826 Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof |
| 01/27/2005 | US20050019824 Fibroblast Growth Factor-10 |
| 01/27/2005 | US20050019823 Using enhanced concentration of transmembrane polypeptide as diagnostic indicator of cell proliferative disorers; diagnosing cancer; antitumor agents |
| 01/27/2005 | US20050019818 Human TBX20 gene and uses |
| 01/27/2005 | US20050019815 Nucleotide sequences coding selenium containing protein for use in diagnosis, prevention and treatment prostate cell proliferative disorders |
| 01/27/2005 | US20050019813 Identifying agents which modulate ubiquination activity ring box protein (RBX1); antitumor agents; enzyme inhibitors |
| 01/27/2005 | US20050019812 Neutral amino acid transporter and gene thereof |
| 01/27/2005 | US20050019811 Neutral amino acid transporter and gene thereof |
| 01/27/2005 | US20050019810 Nucleotide sequences coding transmembrane protein (TANGO) for use as tool in detection of modulator for prevention and treatment of inflammation and cell proliferative disorders |
| 01/27/2005 | US20050019766 Nucleotide sequences coding iron sulfur protein (ISP-1) and or cytochrome b locus (CTB-1) protein for use as tool in detection of modulators for treatment, prevention or ameloriation of developmental, behavioral, reproductive and aging disorders |
| 01/27/2005 | US20050019763 Isolated polypeptide of given sequence; expression vectors, host cells, antibodies, agonists, and antagonists; use in diagnosing, treating, or preventing various disorders |
| 01/27/2005 | US20050019758 Reactive with F protein epitope of Respiratory Syncytial Virus and capable of neutralizing infection; use in prophylactic immunotherapy |
| 01/27/2005 | US20050019754 Peptides of given sequence with immunogenic epitopes activating CD8+ class I major histocompatibility complex restricted cytotoxic T-lymphocytes for patients harboring latent HCMV infection in the absence of active viral replication; using enriched antigen presenting cells; vaccines |
| 01/27/2005 | US20050019743 Improved blood product suitable for use in transfusions comprising inhibitor of glycoprotein Ib alpha cleavage, such as a metalloproteinase or TACE inhibitor |
| 01/27/2005 | US20050019423 Method for treating amyotrophic lateral sclerosis |
| 01/27/2005 | US20050019417 stabilization of proteins, peptides or cells by fluidization of microparticles to form fluidized bed of microparticles comprising water soluble gel forming solid particles, then spraying coating with liquids comprising sugars and solvents, and drying |
| 01/27/2005 | US20050019392 Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| 01/27/2005 | US20050019386 In mixture of membrane-forming amphiphiles subjected to high pressure homogenization or ultrasound; contain immunomodulator, cyclosporin, and/or at least one cytokine or polyethylene glycol-cytokines |
| 01/27/2005 | US20050019382 Continuous production of solvent-free and mastication-free pressure senstive adhesive styrene block copolymer (SBC); supplying, compounding, homogenizing |
| 01/27/2005 | US20050019370 Drug delivery device containing viable cells implanted into blood vessel; cells produce and secrete the pre-selected molecule into systemic circulation; capsule held in place by anchored blood permeable element |
| 01/27/2005 | US20050019367 Continuous release of luteinizing hormone releasing hormone (lh-rh) analogue of leuprorelin, buserelin, triptorelin, and/or goserelin |
| 01/27/2005 | US20050019346 Nucleic acids and regulatory sequences; gene expression; antitumor agents |
| 01/27/2005 | US20050019343 administering an effective dose of a polypeptide comprising an immunogenic fragment of A beta (SEQ ID NO:1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the A beta fragment; Alzheimer's disease |
| 01/27/2005 | US20050019342 Mixture cancer immunotherapy and adjuvant; anticancer agents |
| 01/27/2005 | US20050019341 Gene that codes tumor antigen is detected by cytotoxic lymphocyte; isolated from Dna libraries |
| 01/27/2005 | US20050019334 Interleukin antibody or fusion protein; comprising active material and FC domain; Escherichia coli cells |
| 01/27/2005 | US20050019331 Moderate neutrophilsin wound area; antiinflammatory agents; wound healing agents |
| 01/27/2005 | US20050019330 administering an antibody that specifically binds to the amyloid deposit or a component thereof; can be a human, humanized, chimeric or nonhuman antibody and can be monoclonal or polyclonal; also a novel monoclonal antibody which specifically binds to an epitope within residues 13-28 of A beta |
| 01/27/2005 | US20050019328 Prevention and treatment of amyloidogenic disease |
| 01/27/2005 | US20050019325 WSX receptor agonist antibodies |
| 01/27/2005 | US20050019324 Peptides and antibodies to muc 1 proteins |
| 01/27/2005 | US20050019322 Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| 01/27/2005 | US20050019320 Controlling food intake; controlling gene expression of G protein; polypeptide |
| 01/27/2005 | US20050019319 aspirin, magnesium, and nattokinase, and either niacin or nitroglycerine, especially in the form of a chewable tablet, nasal spray, or suppository |
| 01/27/2005 | US20050019318 Contraceptices; controlling vasculation; antiproliferative agents; anticancer agents; administering protease |
| 01/27/2005 | US20050019317 Synergistic mixture in capsules |
| 01/27/2005 | US20050019315 Odor control compositions and methods |
| 01/27/2005 | US20050019313 Genetic engineering; supplying stem cells; genes code cytosine deaminase; central nervous system tumors |
| 01/27/2005 | US20050019307 Therapy gene against mammary gland cancer; transcription control ; Dna |
| 01/27/2005 | US20050019306 Hybrid fusion protein transcription regulator to induce interferon target gene expression |
| 01/27/2005 | US20050019305 Inhibiting ligand/receptor interactions involving immunoglobulins, interleukins, interferon-alpha, histamine and/or leukotrienes; long term relief; kits |
| 01/27/2005 | US20050019304 Novel human mage-like protein |
| 01/27/2005 | US20050019301 Use of an extract from the vigna aconitifolia plant in a cosmetic and/or dermopharmaceutical composition |
| 01/27/2005 | US20050019297 Protein derived composition for skin care using spider silk protein or an analog with adjuvants |
| 01/27/2005 | US20050019271 Glycopyrrolate in sustained releae form; antimuscarinic agents |
| 01/27/2005 | CA2819769A1 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 01/27/2005 | CA2573060A1 Asymmetric disulfides and methods of using same |
| 01/27/2005 | CA2539190A1 Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
| 01/27/2005 | CA2533522A1 Amino acid-substituted coagulation factor v |
| 01/27/2005 | CA2533314A1 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 01/27/2005 | CA2532789A1 Methods and compositions for controlling ectoparasites |
| 01/27/2005 | CA2532664A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 01/27/2005 | CA2532630A1 Use of lymphocytes transformed with .alpha.-2-heremans-schmid glycoprotein (ahsg) to treat tgf-.beta.-mediated cancer |
| 01/27/2005 | CA2532595A1 Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin |
| 01/27/2005 | CA2532542A1 Treatment or prevention of damage due to radiation exposure |
| 01/27/2005 | CA2532475A1 Formulation for a protein pharmaceutical without added human serum albumin (hsa) |
| 01/27/2005 | CA2532352A1 Methods and pharmaceutical compositions for healing wounds |
| 01/27/2005 | CA2532138A1 Injection of bone marrow-derived cells and medium for angiogenesis |
| 01/27/2005 | CA2532127A1 Regulatory t-cells containing galectins for the therapy and diagnosis of diseases |
| 01/27/2005 | CA2532013A1 Peptido-mimetic compounds containing rgd sequence useful as integrin inhibitors; and intermediates thereof |
| 01/27/2005 | CA2531695A1 Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
| 01/27/2005 | CA2531322A1 A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 01/27/2005 | CA2529777A1 Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells |
| 01/27/2005 | CA2528383A1 Inactivators and bivalent inhibitors of glyoxalase i and methods of inhibiting tumor growth |
| 01/27/2005 | CA2528372A1 Inhibition of apoptosis-specific elf-5a ("eif-5a1") with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics |
| 01/27/2005 | CA2522508A1 Antisense antiviral agent and method for treating ssrna viral infection |
| 01/26/2005 | EP1500702A1 APO-2LI and APO-3 apoptosis polypeptides from the TNFR1 familiy |
| 01/26/2005 | EP1500662A2 Stabilizing peptides |
| 01/26/2005 | EP1500403A1 Preventive/remedy for diabetes |
| 01/26/2005 | EP1500399A1 Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases |
| 01/26/2005 | EP1500390A1 Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof |
| 01/26/2005 | EP1500386A1 Method for time-dependent decrease of ph in a cosmetic composition and a composition for permanent hair shaping with time-dependent decrease of the wave-shaping efficiency |
| 01/26/2005 | EP1499898A2 Regulation of tnf-alpha |